Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2-mutated Langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib.

Human pathology - 1 Mar 2018

Bonometti Arturo, Bagnoli Filippo, Fanoni Daniele, Venegoni Luigia, Corti Laura, Bianchi Paola, Elli Elena Maria, Isimbaldi Giuseppe, L'Imperio Vincenzo, Nazzaro Gianluca, Passoni Emanuela, Berti Emilio

Abstract excerpt

The pathogenesis and cellular origin of Langerhans cell histiocytosis (LCH) are debated. Recently, mutations on MAPK and PI3K pathways have been linked to disrupted cell proliferation in LCH. Janus Kinase 2 (JAK2) mutations play the same role in Philadelphia-negative chronic myeloproliferative neoplasms. We describe the case of a patient affected by JAK2-positive primary myelofibrosis (PMF) who developed a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Histiocytosis, Langerhans-Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Mutation

Share to Nitriles

Share to Primary Myelofibrosis

Share to Pyrazoles

Share to Pyrimidines

Source

Identifiers

PMID: 29107666
DOI: 10.1016/j.humpath.2017.10.017

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2-mutated Langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib.PMID 29107666Read ↗

Langerhans cell histiocytosis: current advances in molecular pathogenesis.Semantic proximity Read ↗

Langerhans cell histiocytosis. Advances in pathogenesis and clinical practice.Semantic proximity Read ↗

Langerhans Cell Histiocytosis: A Clinicopathologic Review and Molecular Pathogenetic Update.Semantic proximity Read ↗

Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy.Semantic proximity Read ↗

Advances in our understanding of genetic markers and targeted therapies for pediatric LCH.Semantic proximity Read ↗

New insights in lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis.Semantic proximity Read ↗

Clinical and prognostic features of Langerhans cell histiocytosis in adults.Semantic proximity Read ↗

[Progress in the Treatment of Adult Langerhans Cell Histiocytosis --Review].Semantic proximity Read ↗

[Pathophysiology and treatment of adult Langerhans cell histiocytosis].Semantic proximity Read ↗

Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasmsSemantic proximity Read ↗

Histiocytic neoplasms in the era of personalized genomic medicine.Semantic proximity Read ↗

Langerhans Cell Histiocytosis and Other Histiocytic Diseases of the Lung.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.